With NIH Funding, Hocus Locus Aims to Develop Novel microRNA Inhibitors | GenomeWeb

NEW YORK (GenomeWeb) – Having just secured its second small business grant from the National Institutes of Health, University at Albany spinout Hocus Locus is aiming to further develop a novel microRNA inhibition technology initially for research applications and, ultimately, as a therapeutic modality.

The approach is based on so-called structurally interacting RNAs, or sxRNAs, which the company believes are part of a post-transcriptional regulatory mechanism that controls RNA binding protein (RBP) interactions with messenger RNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.